Clinical Trials Logo

Breakthrough Cancer Pain clinical trials

View clinical trials related to Breakthrough Cancer Pain.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03564548 Recruiting - Cancer Clinical Trials

Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain

REBORN
Start date: May 26, 2021
Phase: Phase 2
Study type: Interventional

Breakthrough cancer pain (BTcP) is a rapid onset, high intensity and short duration pain episode, which takes place within stable background pain control. It significantly affects the quality of life of patients with cancer and their ability to function normally. Rapid onset opioids and immediate-release oral opioids (e.g. morphine sulfate, hydromorphone, and oxycodone) are the standard treatment for BTcP. Because of the limited availability, high cost, complicated titration and the high risks of overdosing with rapid-onset opioids, most often the preferred choice of treatment is immediate-release oral opioids. However, this approach might not always offer optimal speed for onset of action and duration to match the rapid nature of an episode of BTcP. In order to seek a potential alternative to immediate-release oral opioids, we are proposing to test the onset of action of PPP001 to rapidly alleviate breakthrough pain in patients with cancer. We will also examine the safety and the efficacy on pain intensity of PPP001 within this population.

NCT ID: NCT01698645 Recruiting - Clinical trials for Breakthrough Cancer Pain

Patient Satisfaction and Quality of Life Impact - PecFent®

Qualipec
Start date: September 2012
Phase: N/A
Study type: Observational

National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions. • Study objectives include assessment of early treatment satisfaction.

NCT ID: NCT01693328 Recruiting - Clinical trials for Breakthrough Cancer Pain

Patient Satisfaction and Quality of Life Impact - PecFent®

Qualipec
Start date: September 2012
Phase: N/A
Study type: Observational

National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions. • Study objectives include assessment of early treatment satisfaction.

NCT ID: NCT00822614 Recruiting - Clinical trials for Breakthrough Cancer Pain

Safety of Fentanyl TAIFUN Treatment

FINDS
Start date: December 2008
Phase: Phase 3
Study type: Interventional

A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group Trial to Evaluate hte Safety of Fentanyl TAIFUN Treatment after titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients on Maintenance Opioid Therapy